Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.39 |
| ▸ | FEN1 | P39748 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 8/20 | 0.39 |
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.33 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1492048 | 0.87 | CYP2C9 (0.48) | MAPTCYP2C9CYP3A4ALOX5APFEN1 | |
| SCHEMBL1437245 | 0.85 | PSIP1 (0.47) | CYP2C9CYP3A4BRAFPTGES2CYP2C19 | |
| SCHEMBL9930639 | 0.81 | CYP2C9 (0.48) | MAPTCYP2C9CYP3A4ALOX5APFEN1 | |
| SCHEMBL1462080 | 0.81 | CYP3A4 (0.56) | CYP2C9CYP3A4BRAFCYP2C19 | |
| SCHEMBL9930938 | 0.80 | BRAF (0.47) | MAPTCYP2C9CYP3A4ALOX5APFEN1 | |
| SCHEMBL1462058 | 0.80 | CYP2C9 (0.46) | MAPTCYP2C9CYP3A4BRAFKMT2A | |
| SCHEMBL1462087 | 0.77 | BRAF (0.49) | CYP2C9CYP3A4BRAFPTGES2CYP2C19 | |
| SCHEMBL19221593 | 0.77 | MAPT (0.46) | MAPTCYP3A4ALOX5APFEN1PTGES2 | |
| SCHEMBL1818143 | 0.72 | CYP2C9 (0.68) | MAPTCYP2C9CYP3A4ALOX5APFEN1 | |
| SCHEMBL9930367 | 0.72 | CYP2C9 (0.57) | MAPTCYP2C9CYP3A4ALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130018033-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2013-01-17 | — | — | US | claimed |
| US-20130018033-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2013-01-17 | — | — | US | disclosed |
| US-20130018033-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2013-01-17 | — | — | US | disclosed |
| US-20130018033-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2013-01-17 | — | — | US | disclosed |
| CN-102712646-A | RAF inhibitor compounds and methods of use thereof | ARRAY BIOPHARMA INC | 2012-10-03 | — | — | CN | disclosed |
| WO-2012118492-A1 | HETEROCYCLIC SULFONAMIDES AS RAF INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-09-07 | — | — | WO | disclosed |
| EP-2493865-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2012-09-05 | — | — | EP | disclosed |
| US-20120157439-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157439-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157439-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2011025938-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2011-03-03 | — | — | WO | disclosed |
| WO-2011025938-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2011-03-03 | — | — | WO | disclosed |
| WO-2011025940-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018033-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | MAPT 1082/4885CYP2C9 2926/4885CYP3A4 2785/4885 |
| US-20120157439-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | MAPT 1082/4885CYP2C9 2926/4885CYP3A4 2785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.